Troxacitabine

Drug Profile

Troxacitabine

Alternative Names: BCH 4556; SGX-145; SPD 758; Troxatyl

Latest Information Update: 24 Mar 2010

Price : $50

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer SGX Pharmaceuticals; Shire
  • Class Antineoplastics; Nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Pancreatic cancer; Renal cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 20 Aug 2008 SGX Pharmaceuticals has been acquired by Eli Lilly
  • 30 Aug 2006 Discontinued - Phase-II/III for Acute myeloid leukaemia in European Union (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top